[go: up one dir, main page]

Davis et al., 1999 - Google Patents

Characterization of the P140K, PVP (138-140) MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy

Davis et al., 1999

Document ID
2450048246115017329
Author
Davis B
Roth J
Liu L
Xu-Welliver M
Pegg A
Gerson S
Publication year
Publication venue
Human gene therapy

External Links

Snippet

The G156A O6-alkylguanine-DNA alkyltransferase (AGT) mutant protein, encoded by the G156A O6-methylguanine-DNA methyltransferase gene (MGMT), is resistant to O6- benzylguanine (BG) inactivation and, after transduction into hematopoietic progenitors …
Continue reading at www.liebertpub.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (-N=N-), diazo (=N2), azoxy (>N-O-N< or N(=O)-N<), azido (-N3) or diazoamino (-N=N-N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Similar Documents

Publication Publication Date Title
Davis et al. Characterization of the P140K, PVP (138-140) MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy
EP1017835B1 (en) Cytochrome p450 reductase for the enhancement of p450-based anti-cancer gene therapy
Chen et al. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene
US5688773A (en) Method of selectively destroying neoplastic cells
Roginskaya et al. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth
US6084085A (en) Inducing resistance to tumor growth with soluble IGF-1 receptor
EP0988059B1 (en) Human quinone reductase 2 conjugates for adept and gdept
Knox et al. CB 1954: from the Walker tumor to NQO2 and VDEPT
WO2001005405A1 (en) Folylpolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity
CA2350776C (en) Novel mitogenic regulators
Yang et al. Mechanisms for ganciclovir resistance in gastrointestinal tumor cells transduced with a retroviral vector containing the herpes simplex virus thymidine kinase gene.
EP0694069A1 (en) Variant insulin-like growth factor i receptor subunits and methods for use thereof
US6770632B1 (en) Folypolyglutamyl synthetase gene transfer to enhance antifolate
EP0910246B1 (en) Use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
EP1539189A2 (en) Method of using anti-apoptotic factors in gene expression
WO2006103452A2 (en) Improved nitroreductase enzymes
EP1575519A2 (en) Cd26-based therapies for cancers and immune disease
US7582606B2 (en) Nadph oxidase cytosolic cofactor mutant
US6887856B1 (en) Protection from ionizing irradiation or chemotherapeutic drug damage by in vivo gene therapy
Olivieri et al. Pharmacologic bone marrow purging: is there any place for etoposide? In vitro comparison with mafosfamide
Davis et al. O6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents
WO2001017533A9 (en) Inhibitor of vascular superoxide anion
AU742176B2 (en) Suppression of malignancy utilizing ribonucleotide reductase R1
Licht et al. Clinical Applications of Gene Therapy in Cancer: Modification of Sensitivity to Therapeutic Agents
Marathi et al. Retroviral transfer of a bacterial alkyltransferase gene (ada) into human bone marrow cells protects against O6-benzylguanine plus 1, 3-bis (2-chloroethyl)-1-nitrosourea cytotoxicity.